Glaucoma is the leading cause of irreversible blindness worldwide, affecting more than 60 million people. In the United States, more than 3 million people suffer from the disease and there are 100,000 new diagnoses annually.
Blindness from glaucoma is associated with significant productivity loss, lower wages and reduced workforce participation as well as costs incurred from social services, occupational health services, rehabilitation, visual assistance devices, transportation and other services that help blind people regain function in society. There is therefore a major benefit to individual patients and society as a whole for successfully treating glaucoma and reducing the disease burden in the U.S. and worldwide.
LayerBio is developing novel drug delivery strategies for treatment of glaucoma. Topical eye drops are the typical method for delivery of medication to the eye, but they have limitations with respect to patient compliance and inability to adequately penetrate deeply into the eye. Alternative delivery strategies are needed to improve therapies for patients with eye disease, and LayerBio is developing novel solutions to address this important problem.